Page 240 - Read Online

Brooks et al. Neurological manifestations in Fabry disease

of cerebral hyperperfusion in Fabry disease. J Neuroimaging 34. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory
2001;11:303-7. controls (DNIC). I. Effects on dorsal horn convergent neurones in the
16. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, rat. Pain 1979;6:283-304.
Barton NW, Schiffmann R. Quantitative analysis of cerebral vascular 35. Dickenson AH, Mathews EA, Suzuki R. Central nervous system
disease in patients with Fabry disease. Neurology 1998;50:1746-9. mechanisms of pain in peripheral neuropathy. In: Hansson PT, Fields
17. Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity HL, RG Hill, Marchettini P, editors. Neuropathic pain: pathophysiology
in the pulvinar on T1-weighted images: a pathognomonic sign of MR and treatment. Seattle: IASP Press; 2001. p. 85-106.
imaging Fabry disease. AJNR Am J Neuroradiol 2003;24:1096-101. 36. Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors
18. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced induced by peripheral nerve injury. Science 1991;251:1608-10.
cerebral blood flow velocity and impaired cerebral autoregulation in 37. Birklein F, Schmelz M, Schifter S, Weber M. The important role
patients with Fabry disease. J Neurol 2004;251:564-70. of neuropeptides in complex regional pain syndrome. Neurology
19. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, 2001;57:2179-84.
Schiffmann R. White matter lesions in Fabry disease Occur in ‘prior’ 38. Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces
selectively hypometabolic and hypoperfusion brain regions. Brain Res pain and Prolonged small fiber dysfunction in Fabry Patients. Pain
Bull 2003;62:231-40. 2000;84:361-5.
20. Saip S, Uluduz D, Erkol G. Fabry disease mimicking multiple 39. Amir R, Michaelis M, Devor M. Membrane potential oscillations
sclerosis. Clin Neurol Neurosurg 2007;109:361-3. in dorsal root ganglion neurons: role in normal electrogenesis and
21. Invernizzi P, Bonometti MA, Turri E, Benedetti MD, Salviati A. A case neuropathic pain. J Neurosci 1999;19:8589-96.
of Fabry disease with central nervous system (CNS) demyelinating 40. Dib-Hajj SD, Fjell J, Cummins TR, Zheng Z, Fried K, LaMotte R,
lesions: a double trouble? Mult Scler 2008;14:1003-6. Black JA, Waxman SG. Plasticity of sodium channel expression in
22. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi DRG neurons in the chronic constriction injury model of neuropathic
M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, pain. Pain 1999;83:591-600.
Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, 41. Tal M, Wall PD, Devor M. Myelinated afferent fiber types that
Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for become spontaneously active and mechanosensitive following nerve
multiple sclerosis: 2010 revisions to the McDonald criteria. Ann transection in the rat. Brain Res 1999;824:218-23.
Neurol 2011;69:292-302. 42. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia
23. Fazekas F, Enzinger C, Schmidt R, Grittner U, Giese AK, Hennerici JM, Barton NW, Schiffmann R. Physiological characterization of
MG, Huber R, Jungehulsing GJ, Kaps M, Kessler C, Martus P, Putaala neuropathy in Fabry’s disease. Muscle Nerve 2002;26:622-9.
J, Ropele S, Tanislav C, Tatlisumak T, Thijs V, von Sarnowski B, 43. Deutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ.
Norrving B, Rolfs A; SIFAP 1 Investigators. Brain magnetic resonance Small fiber dysfunction predominates in Fabry neuropathy. J Clin
imaging findings fail to suspect Fabry disease in young patients with Neurophysiol 2002;19:575-86.
an acute cerebrovascular event. Stroke 2015;46:1548-53. 44. Dyck PJ, O’Brien PC, Kosanke JL, Gillen DA, Karnes JL. The 4,
24. Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata 2, and 1 stepping algorithm for quick and accurate estimation of
G. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des cutaneous sensation threshold. Neurology 1993;43:1508-12.
2013;19:5974-96. 45. Dyck PJ, Zimmerman I, Gillen DA, Johnson D, Karnes JL, O’Brien
25. Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of PC. Cool, warm, and heat-pain detection thresholds: testing methods
family history. J Genet Couns 2008;17:79-83. and inferences about anatomic distribution of receptors. Neurology
26. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral 1993;43:1500-8.
vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am 46. Maag R, Binder A, Maier C, Scherens A, Toelle T, Treede RD, Baron
J Physiol 1996;271:H1262-6. R. Detection of the characteristic painful neuropathy in Fabry disease:
27. Sakurai Y, Kojima H, Shiwa M, Ohashi T, Eto Y, Moriyama H. The a pilot study. Pain Med 2008;9:1217-23.
hearing status in 12 female and 15 male Japanese Fabry patients. Auris 47. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB,
Nasus Larynx 2009;36:627-32. McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG,
28. Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The Desnick RJ; Fabry Disease Clinical Trial Study Group. Agalsidase-
vascular dementia of Fabry’s disease. Dement Geriatr Cogn Disord beta therapy for advanced Fabry disease: a randomized trial. Ann
1997;8:252-7. Intern Med 2007;146:77-86.
29. Liston EH, Levine MD, Philippart M. Psychosis in Fabry disease and 48. Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann
treatment with phenoxybenzamine. Arch Gen Psychiatry 1973;29:402-3. RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S,
30. Grewal RP. Psychiatric disorders in Patients with Fabry’s disease. Int Warnock DG, Weinreb NJ, Wilcox WR. Ten-year outcome of enzyme
J Psychiatry Med 1993;23:307-12. replacement therapy with agalsidase beta in patients with Fabry
31. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, disease. J Med Genet 2015;52:353-8.
Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M. Fabry 49. Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick
disease: baseline medical characteristics of a cohort of 1765 males and RJ, Sims K. Enzyme replacement therapy stabilized white matter
females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-92. lesion progression in Fabry disease. Cerebrovasc Dis 2014;38:448-56.
32. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, 50. Tsuboi K, Yamamoto H, Somura F, Goto H. Successful management of
Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M. enzyme replacement therapy in related fabry disease patients with severe
Fabry disease defined: baseline clinical manifestations of 366 patients adverse events by switching from agalsidase Beta (fabrazyme(®)) to
in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42. agalsidase alfa (replagal (®)). JIMD Rep 2015;15:105-11.
33. MacDermot J, MacDermot KD. Neuropathic pain in Anderson- 51. Politei J, Schenone AB, Cabrera G, Heguilen R, Szlago M. Fabry disease
Fabry disease: pathology and therapeutic options. Eur J Pharmacol and enzyme replacement therapy in classic patients with same mutation:
2001;429:121-5. different formulations - different outcome? Clin Genet 2016;89:88-92.

Neuroimmunology and Neuroinflammation ¦ Volume 3 ¦ October 28, 2016 231